肿瘤专科医院药品不良反应报告73例分析  

Analysis of 73 ADR Cases in Tumor Hospital

作　　者：王宇[1] 杨珺[1] 盛明宇[1] 石虹[1] 马金兰[1] 

机构地区：[1]中国医学科学院肿瘤医院药剂科,北京100021

出　　处：《中国药物应用与监测》2009年第4期236-238,共3页Chinese Journal of Drug Application and Monitoring

摘　　要：目的:对肿瘤患者药品不良反应(ADR)监测的现状进行分析,为今后开展ADR监测工作提供依据。方法:采用回顾性研究方法对我院2008年上报的73例ADR报告进行分类统计,分析ADR发生规律及其特点。结果:73例报表中,用药途径主要为静脉注射,共计63例(86.3%);涉及药物31种,主要为抗肿瘤药物(45.2%);ADR主要表现是全身性损害(27.4%)和呼吸系统损害(21.9%),其次是皮肤及其黏膜的损害。结论:应加强对肿瘤患者ADR的监测工作,以保证用药安全性。Objective： To analyze the current situation of adverse drug reactions （ADRs） monitoring in the tumor patients, and provide evidences for ADR monitoring in the future. Methods： 73 ADR reports collected in 2008 in our hospital were analyzed retrospectively in order to find the characteristics and regularity of ADRs in the tumor patients. Results： Among the 73 ADR cases, 63 cases （accounting for 86.3%） were induced by intravenous injection. 31 Categories of drugs were involved in the ADRs, among which the anticancer drugs ranked the first （45.2%）. The main clinical manifestations of ADRs were systemic damages （27.4%） and respiratory system disorders （21.9%）, and then followed by the lesions of skin and mucous membrane. Conclusion： ADR monitoring in the tumor patients should be strengthened in order to ensure the safety of drug use.

关 键 词：肿瘤患者 药品不良反应 监测 合理用药 

分 类 号：R95[医药卫生—药学]